Skip To Main Content
Michele Basso on Muck Rack

Michele Basso

United States
As seen in: Nature, MDPI, Science Magazine, Cell Reports, The Lancet, Cell Press, Mary Ann Liebert, Inc., JNeurosci, Future Medicine, Future Oncology
Scientist and Professor Passionate Advocate for humane and responsible research involving animals. #thankamonkey #endsufferingthruscience Views are my own
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michele

Contact Michele, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Alternatives to animal research are not inherently more ethical

|
By Michele Basso
| Nature Verified
CORRESPONDENCE 02 December 2025 Two Comment articles on reforms to animal research rightly call for compassion and innovation (T. J. Herron et al. Nature 646, 799–801 (2025); K. C. K. Lloyd Nature 646, 802–803; 2025). But ending animal studies is premature, and other options, known as new approach methodologies or novel alternative methods (NAMs), are not morally pure.
Open in Who Shared Issue with article?

Science must break its silence to rebuild public trust - Nature Neuroscience

|
By Cory Miller, Michele Basso, Aaron P. Batista, Katalin M. Gothard, Karen Parker, Doris Tsao, Ziv M. Williams
| Nature Verified
This Comment calls on scientists to acknowledge how insufficient communication and limited engagement beyond academia have deepened the divide between science and the public. Restoring trust requires a paradigm shift in which scientists accept that the responsibility to champion science lies with us.
Open in Who Shared Issue with article?

Unexplained early deaths in EMERALD-1: is liver failure the reason?

|
By Giovanni Trovato, Michele Basso
| The Lancet Verified
We read with great interest the Article on the EMERALD-1 trial.1 The primary endpoint of the trial was progression-free survival and, for 78 patients, death occurred before progression: 37 (27%) of 136 patients in the durvalumab plus bevacizumab group, 24 (17%) of 144 patients in the durvalumab plus placebo group, and 17 (11%) of 149 patients in the placebo group.
Open in Who Shared Issue with article?
See all 19 articles